Get started
Author

Jhomary S. Molden

Observed names: J. Molden, Jhomary Molden, Jhomary S Molden
ORCID: 0000-0001-6244-0827
Observed ORCID: 0000-0001-6244-0827
OpenAlex ID: A5079641781
The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques
2020 · Gabriela M. Webb, Jhomary Molden, et al. · PLoS Pathogens · 61
PDF
CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection
2022 · Mary S. Pampusch, Hadia M. Abdelaal, et al. · PLoS Pathogens · 45
PDF
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models
2024 · Stefano Rossetti, Aaron Broege, et al. · npj Breast Cancer · 33
Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway
2024 · Adrish Sen, Salmaan Khan, et al. · Molecular Oncology · 16
PDF
Functional Analysis of the PI3K/AKT/mTOR Pathway Inhibitor, Gedatolisib, Plus Fulvestrant with and Without Palbociclib in Breast Cancer Models
2025 · Aaron Broege, Stefano Rossetti, et al. · International Journal of Molecular Sciences · 12
PDF
Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib
2024 · Aaron Broege, Stefano Rossetti, et al. · Cancers · 9
PDF
Middle-School Student Engagement in a Tick Testing Community Science Project
2021 · Amy Prunuske, Cole Fisher, et al. · Insects · 4
PDF
Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy
2025 · Salmaan Khan, Jhomary Molden, et al. · International Journal of Molecular Sciences · 2
PDF
Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.
2023 · Adrish Sen, Salmaan A Khan, et al. · Journal of Clinical Oncology · 2
Abstract PS2-11-30: Functional analysis of gedatolisib combined with fulvestrant and/or palbociclib in breast cancer cell models adapted to estrogen receptor and/or CDK4/6 inhibitors
2026 · S. Rossetti, A. Broege, et al. · Clinical Cancer Research · 1
Abstract 4928: Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status
2023 · Stefano Rossetti, Aaron Broege, et al. · Cancer Research · 1
Synergistic efficacy of gedatolisib and darolutamide in prostate cancer to overcome resistance to androgen-targeted therapy.
2026 · Stefano Rossetti, Salmaan Khan, et al. · Journal of Clinical Oncology
PDF
Abstract P2-02-07: Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions
2025 · Stefano Rossetti, Aaron Broege, et al. · Clinical Cancer Research
Abstract P2-02-05: Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models
2025 · Stefano Rossetti, Aaron Broege, et al. · Clinical Cancer Research
Author response for "Assessments of prostate cancer cell functions highlight differences between a pan‐ PI 3 K /m TOR inhibitor, gedatolisib, and single‐node inhibitors of the PI 3 K / AKT /m TOR pathway"
2024 · Adrish Sen, Salmaan Khan, et al. · Publons reviews and discussion
Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models
2024 · Stefano Rossetti, Aaron Broege, et al. · Cancer Research
Works count: 16
Citation count: 186
H-index: 6
I10-index: 5
Year
Topic
Type